Rabia Öztaş Kara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rabia Öztaş Kara has a total of 291 co-authors. Here are the top co-authors by number of shared publications:
- Marcus Maurer
Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
7 shared publications - Ana Maria Giménez Arnau
Department of Dermatology Hospital del Mar Research Institute Barcelona Spain
5 shared publications Bahar Sevimli Dikicier
Department of Dermatology Sakarya University Faculty of Medicine Sakarya Turkey
5 shared publications- Dorota Krasowska
Chair and Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, Staszica 11, 20-081 Lublin, Poland
5 shared publications - Emek Kocatürk
Institute of Allergology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
5 shared publications - Ivan Cherrez-Ojeda
Universidad Espíritu Santo Samborondón Ecuador
5 shared publications
Latest Publications
- Open Access
- 3 October 2026
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 26 (10) , 1125-1137
Biologic therapies for adult chronic urticaria: what works, what doesn’t, and why
Chronic spontaneous urticaria (CSU) remains uncontrolled in many adults despite antihistamines and anti-immunoglobulin E (IgE) therapy. The expanding therapeutic landscape includes validated biologic options, promising investigational mechanisms, and unsuccessful therapeutic programs. This narrative review integrates guidelines, randomized trials, regulatory information, systematic reviews, and cohort studies identified through PubMed/MEDLINE and ClinicalTrials.gov searches through 20 July 2026, with targeted updates during revision. It evaluates anti-IgE therapies, interleukin-4/interleukin-13 blockade, KIT receptor-directed mast-cell depletion, other biologic pathways, and non-biologic small molecules for context. Biomarkers, safety, negative trials, and disease modification are examined. Omalizumab remains the benchmark therapeutic agent. Dupilumab inhibits interleukin-4/interleukin-13 signaling and is approved for CSU and several type 2 and other inflammatory conditions. Remibrutinib is an oral Bruton tyrosine kinase inhibitor with efficacy across IgE-defined subgroups, supporting its relevance beyond a single proposed autoimmune endotype. Anti-KIT therapy is a leading investigational biologic strategy. Biomarkers should inform response probabilities rather than rigid prescribing decisions. Definitive disease modification remains unproven.
- 3 October 2026
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 26 (10) , 1125-1137
Open AccessBiologic therapies for adult chronic urticaria: what works, what doesn’t, and why
Chronic spontaneous urticaria (CSU) remains uncontrolled in many adults despite antihistamines and anti-immunoglobulin E (IgE) therapy. The expanding therapeutic landscape includes validated biologic options, promising investigational mechanisms, and unsuccessful therapeutic programs. This narrative review integrates guidelines, randomized trials, regulatory information, systematic reviews, and cohort studies identified through PubMed/MEDLINE and ClinicalTrials.gov searches through 20 July 2026, with targeted updates during revision. It evaluates anti-IgE therapies, interleukin-4/interleukin-13 blockade, KIT receptor-directed mast-cell depletion, other biologic pathways, and non-biologic small molecules for context. Biomarkers, safety, negative trials, and disease modification are examined. Omalizumab remains the benchmark therapeutic agent. Dupilumab inhibits interleukin-4/interleukin-13 signaling and is approved for CSU and several type 2 and other inflammatory conditions. Remibrutinib is an oral Bruton tyrosine kinase inhibitor with efficacy across IgE-defined subgroups, supporting its relevance beyond a single proposed autoimmune endotype. Anti-KIT therapy is a leading investigational biologic strategy. Biomarkers should inform response probabilities rather than rigid prescribing decisions. Definitive disease modification remains unproven.
- Open Access
- 14 September 2026
- Published by Galenos Yayinevi in TURKDERM
Challenges and experiences of dermatologists in managing chronic urticaria
Challenges and experiences of dermatologists in managing chronic urticaria - Turkderm-Turkish Archives of Dermatology and Venereology
- 14 September 2026
- Published by Galenos Yayinevi in TURKDERM
Open AccessChallenges and experiences of dermatologists in managing chronic urticaria
Challenges and experiences of dermatologists in managing chronic urticaria - Turkderm-Turkish Archives of Dermatology and Venereology
- Open Access
- 8 September 2026
- Published by Wiley in JEADV Clinical Practice
Impact of Chronic Urticaria on Major Life‐Changing Decisions: Greater Burden in Social, Physical, and Job/Career Domains
Background: Chronic urticaria (CU) is a common condition associated with a substantial burden on patients and society, characterized by persistent symptoms and reduced sense of life control. Although existing patient‐reported outcome measures (PROMs) assess disease activity and quality of life, they largely reflect the current disease state, and evidence on CU's long‐term impact on major life‐changing decisions (MLCDs) remains scarce. Objectives: To evaluate CU's long‐term impact on MLCDs and assess the validity and reliability of the Turkish MLCDP. Methods: The MLCDP is a 32‐item questionnaire assessing the impact of chronic diseases on MLCDs across five domains. A linguistically validated Turkish version was developed using a forward–backward translation process. In this multicentre cross‐sectional study, 111 Turkish‐speaking CU patients (≥ 16 years) completed the MLCDP and other PROMs during follow‐up visits. Results: CU affected at least one MLCD in 79.3%, impacting social (77, 69.4%), physical (63, 56.8%), job/career (41, 36.9%), family/relationships (23, 20.7%) and education (9, 8.1%) domains. The most commonly affected decisions of each domain were changing eating habits (67, 60.4%), not taking part in any sport activities (35, 31.5%), working flexible hours (26, 23.4%), not having a sexual relationship (16, 14.4%) and studying near home (6, 5.4%), respectively. Patients with disease onset ≤ 45 years had higher rates of at least one affected MLCD than those > 45 years (74, 82.2% vs. 10, 58.8%, p < 0.05). Similarly, patients with an emergency referral in the last year (30, 93.8% vs. 58, 74.4%) and those who missed school/workdays in the last year (24, 100% vs. 64, 73.6%) showed higher rates of at least one affected MLCD compared with those without (all p < 0.05). Limitations: The small sample size, single‐cohort cross‐sectional design, lack of controls, self‐reported measures, inclusion of patients with short disease duration and unassessed potential confounders such as comorbidities, medications and personality traits. Conclusions: CU has a long‐term impact on major life‐changing decisions, especially in social, physical, and job/career decisions of the patients. Younger patients and those with severe disease are particularly affected.
- 8 September 2026
- Published by Wiley in JEADV Clinical Practice
Open AccessImpact of Chronic Urticaria on Major Life‐Changing Decisions: Greater Burden in Social, Physical, and Job/Career Domains
Background: Chronic urticaria (CU) is a common condition associated with a substantial burden on patients and society, characterized by persistent symptoms and reduced sense of life control. Although existing patient‐reported outcome measures (PROMs) assess disease activity and quality of life, they largely reflect the current disease state, and evidence on CU's long‐term impact on major life‐changing decisions (MLCDs) remains scarce. Objectives: To evaluate CU's long‐term impact on MLCDs and assess the validity and reliability of the Turkish MLCDP. Methods: The MLCDP is a 32‐item questionnaire assessing the impact of chronic diseases on MLCDs across five domains. A linguistically validated Turkish version was developed using a forward–backward translation process. In this multicentre cross‐sectional study, 111 Turkish‐speaking CU patients (≥ 16 years) completed the MLCDP and other PROMs during follow‐up visits. Results: CU affected at least one MLCD in 79.3%, impacting social (77, 69.4%), physical (63, 56.8%), job/career (41, 36.9%), family/relationships (23, 20.7%) and education (9, 8.1%) domains. The most commonly affected decisions of each domain were changing eating habits (67, 60.4%), not taking part in any sport activities (35, 31.5%), working flexible hours (26, 23.4%), not having a sexual relationship (16, 14.4%) and studying near home (6, 5.4%), respectively. Patients with disease onset ≤ 45 years had higher rates of at least one affected MLCD than those > 45 years (74, 82.2% vs. 10, 58.8%, p < 0.05). Similarly, patients with an emergency referral in the last year (30, 93.8% vs. 58, 74.4%) and those who missed school/workdays in the last year (24, 100% vs. 64, 73.6%) showed higher rates of at least one affected MLCD compared with those without (all p < 0.05). Limitations: The small sample size, single‐cohort cross‐sectional design, lack of controls, self‐reported measures, inclusion of patients with short disease duration and unassessed potential confounders such as comorbidities, medications and personality traits. Conclusions: CU has a long‐term impact on major life‐changing decisions, especially in social, physical, and job/career decisions of the patients. Younger patients and those with severe disease are particularly affected.
- Open Access
- 17 March 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 631-645
Factors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study
Background and Objective Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally. Methods The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD. Results Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease. Conclusions Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online] Graphical Abstract
- 17 March 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (3) , 631-645
Open AccessFactors Associated with Symptomatic Dermographism: Findings from the UCARE PREVALENCE-D Study
Background and Objective Symptomatic dermographism (SD), the most common chronic inducible urticaria subtype, manifests as strip-shaped, pruritic wheals after skin friction. Conclusive data on its associated factors are limited, and direct comparisons between individuals with and without SD remain scarce. We aimed to identify factors associated with SD internationally. Methods The PREVALENCE-D (Prevalence Estimation of Dermographism) study was an international cross-sectional survey conducted from 2021 to 2024 across 19 countries. An expert-designed questionnaire diagnosed SD and assessed potential associated factors. SD participants were defined as those who self-reported chronic recurrent urticarial dermographism with itch. Factors associated with SD were identified by comparing participants with and without SD. Results Of 68,513 participants, 3101 had SD (female 73.3%). Their mean age was 40.2 ± 16.2 years. Key factors associated with SD included atopic dermatitis (adjusted odds ratio [aOR] 4.20, 95% confidence interval [CI] 3.62‒4.88) and allergic rhinitis (aOR 2.11, 95% CI 1.88‒2.37). Participants with at least one atopic condition (allergic rhinitis, atopic dermatitis, or asthma) were significantly more likely to have SD (aOR 2.70, 95% CI 2.47‒2.95). Those with all three atopic conditions had a further increased likelihood of SD (aOR 7.75, 95% CI 5.31‒11.29). Other associations included working and older age groups, female sex, dyslipidemia, and thyroid disease. Conclusions Atopic dermatitis and allergic rhinitis emerged as the strongest correlates of SD, especially those with all three atopic conditions. Thus, allergic comorbidities should be assessed in SD patients. Further research is needed to clarify the pathophysiological relationship between these conditions and SD. [Graphical abstract available online] Graphical Abstract
- Open Access
- 18 February 2026
- Published by Springer Nature in Mycopathologia
- Vol. 191 (2) , 34
Clinical and Mycological Profiles of Chronic and Recalcitrant Dermatophytosis: Türkiye, 2022–2024
This study investigated the treatment outcomes of 91 patients with chronic and recalcitrant dermatophytosis from 20 hospitals in Türkiye between June 2022 and March 2024, as well as the in vitro antifungal susceptibility and squalene epoxidase ( SQLE ) substitution profiles of the dermatophytes obtained from these patients. Molecular identification by sequencing 91 isolates, revealed 76 Trichophyton mentagrophytes ITS genotype VIII (TmVIII; also known as T . indotineae ) isolates, 13 Trichophyton rubrum , one Trichophyton tonsurans , and one Microsporum canis . The Phe397Leu substitution predominated in the SQLE , and Tyr414His co-occurred in nine TmVIII isolates. Five novel substitutions were observed in TmVIII. Among 13 T . rubrum isolates, three showed different SQLE substitution patterns compared to the wild-type strain. EUCAST antifungal susceptibility testing revealed high minimum inhibitory concentrations (MICs) for terbinafine (TRB) (> 0.25 mg/L) and for fluconazole (FLZ) (≥ 16 mg/L), indicating resistance in most TmVIII isolates. Of the 91 patients, 83 responded to FLZ, itraconazole (ITZ), TRB, or voriconazole-based regimens. While adjunct therapy with FLZ and resveratrol (RES) led to improvement in 28/29 patients despite their high in vitro inhibition concentrations, ITZ and curcumin (CUR) therapy was successful in 3/3 patients. However, the in vitro efficiency of CUR could not be evaluated. These findings highlight the local occurrence of specific SQLE substitutions, underscore the importance of EUCAST MIC testing combined with SQLE sequencing for surveillance, and support further evaluation of RES and CUR as an adjunct in TRB-resistant TmVIII.
- 18 February 2026
- Published by Springer Nature in Mycopathologia
- Vol. 191 (2) , 34
Open AccessClinical and Mycological Profiles of Chronic and Recalcitrant Dermatophytosis: Türkiye, 2022–2024
This study investigated the treatment outcomes of 91 patients with chronic and recalcitrant dermatophytosis from 20 hospitals in Türkiye between June 2022 and March 2024, as well as the in vitro antifungal susceptibility and squalene epoxidase ( SQLE ) substitution profiles of the dermatophytes obtained from these patients. Molecular identification by sequencing 91 isolates, revealed 76 Trichophyton mentagrophytes ITS genotype VIII (TmVIII; also known as T . indotineae ) isolates, 13 Trichophyton rubrum , one Trichophyton tonsurans , and one Microsporum canis . The Phe397Leu substitution predominated in the SQLE , and Tyr414His co-occurred in nine TmVIII isolates. Five novel substitutions were observed in TmVIII. Among 13 T . rubrum isolates, three showed different SQLE substitution patterns compared to the wild-type strain. EUCAST antifungal susceptibility testing revealed high minimum inhibitory concentrations (MICs) for terbinafine (TRB) (> 0.25 mg/L) and for fluconazole (FLZ) (≥ 16 mg/L), indicating resistance in most TmVIII isolates. Of the 91 patients, 83 responded to FLZ, itraconazole (ITZ), TRB, or voriconazole-based regimens. While adjunct therapy with FLZ and resveratrol (RES) led to improvement in 28/29 patients despite their high in vitro inhibition concentrations, ITZ and curcumin (CUR) therapy was successful in 3/3 patients. However, the in vitro efficiency of CUR could not be evaluated. These findings highlight the local occurrence of specific SQLE substitutions, underscore the importance of EUCAST MIC testing combined with SQLE sequencing for surveillance, and support further evaluation of RES and CUR as an adjunct in TRB-resistant TmVIII.
- Open Access
- 5 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8) , 1406-1419
Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study
Background: Chronic spontaneous urticaria (CSU) can cause psychosocial and quality of life burden on patients and their family members and caregivers. Despite its recognition as a debilitating disease, limited data exist regarding the impact of CSU on family members, hindering a comprehensive understanding of the disease's broader effects. This study aimed to assess how CSU affects the quality of life of family members who support patients in their daily challenges by applying the Family Dermatology Life Quality Index (FDLQI) questionnaire across multiple countries. Methods: A cross‐sectional, multicentre and international study conducted between January and December 2024 in Urticaria Centres of Reference and Excellence (UCARE) centres located in several countries including Brazil, China, Ecuador, Greece, India, Oman, Poland, Russia, Thailand, Turkey, Peru and North Macedonia. Statistical analyses, including non‐parametric tests and multiple regression models, were employed to explore associations between disease severity/control and family burden. Results: Poorly controlled CSU significantly deteriorated family members' quality of life, particularly in emotional, physical and social domains. Higher disease severity and lower disease control scores were associated with increased stress, greater caregiving burden and elevated health expenditures. In opposition to family relations, older age and longer time since diagnosis mitigate negative impacts, while insufficient treatment regimens exacerbated them. Conclusions: Inadequate control of CSU amplifies the burden on families, underscoring the need for effective and supportive care strategies.
- 5 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (8) , 1406-1419
Open AccessFamily quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study
Background: Chronic spontaneous urticaria (CSU) can cause psychosocial and quality of life burden on patients and their family members and caregivers. Despite its recognition as a debilitating disease, limited data exist regarding the impact of CSU on family members, hindering a comprehensive understanding of the disease's broader effects. This study aimed to assess how CSU affects the quality of life of family members who support patients in their daily challenges by applying the Family Dermatology Life Quality Index (FDLQI) questionnaire across multiple countries. Methods: A cross‐sectional, multicentre and international study conducted between January and December 2024 in Urticaria Centres of Reference and Excellence (UCARE) centres located in several countries including Brazil, China, Ecuador, Greece, India, Oman, Poland, Russia, Thailand, Turkey, Peru and North Macedonia. Statistical analyses, including non‐parametric tests and multiple regression models, were employed to explore associations between disease severity/control and family burden. Results: Poorly controlled CSU significantly deteriorated family members' quality of life, particularly in emotional, physical and social domains. Higher disease severity and lower disease control scores were associated with increased stress, greater caregiving burden and elevated health expenditures. In opposition to family relations, older age and longer time since diagnosis mitigate negative impacts, while insufficient treatment regimens exacerbated them. Conclusions: Inadequate control of CSU amplifies the burden on families, underscoring the need for effective and supportive care strategies.
- 31 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1838-1845
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study
Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.
- 31 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1838-1845
Dysmenorrhea in Chronic Spontaneous Urticaria: A Subset of Patients Report Worsening and Partial Antihistamine Benefit: UCARE HURDLE ‐I Study
Background: Histamine plays a central role in CSU pathogenesis and may contribute to extracutaneous symptoms such as dysmenorrhea, but this relationship has not been fully examined. Methods: In this prospective, cross‐sectional multicenter study, 425 female CSU patients and 370 age‐matched controls were recruited from 19 UCARE centers in Türkiye. Dysmenorrhea prevalence and severity were assessed using a numerical scale and symptom scores. Histamine skin prick testing (SPT) was performed to evaluate histamine clearance capacity. Associations between dysmenorrhea, CSU phenotype, antihistamine use, and SPT kinetics were analyzed. Results: The prevalence and severity of dysmenorrhea were comparable between CSU patients and controls (81.6% vs. 79.5%, p = 0.244). However, 95/418 (22.7%) of CSU patients reported increased menstrual pain following CSU onset, and 20/95 (21.1%) of these reported partial relief with antihistamines. CSU patients with worsened dysmenorrhea exhibited significantly shorter histamine SPT positivity durations than those without symptom change (35 vs. 45 min; p = 0.015). No correlation was observed between dysmenorrhea severity and total IgE, anti‐TPO levels, or urticaria control/activity scores. A moderate negative correlation was found between UAS7 and elapsed time to histamine SPT negativity ( r = −0.389, p < 0.001). Conclusions: Although overall prevalence and severity of dysmenorrhea were similar in CSU patients and healthy controls, about one in five patients with CSU experienced worsening menstrual pain after disease onset, and only a subset of these patients reported partial improvement with antihistamines. A distinct CSU subgroup with heightened menstrual pain may be characterized by altered histamine dynamics. Whether these patients may benefit from more intensive antihistamine treatment remains uncertain and requires confirmation in future studies; further studies should explore neuroimmune and hormonal mechanisms underlying this overlap.
- Open Access
The Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
Open AccessThe Prevalence of Symptomatic Dermographism: Results of the International UCARE PREVALENCE ‐D Study
Background: The prevalence of symptomatic dermographism ( SD ) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE ‐D (Prevalence Estimation of Dermographism) study was the largest international, cross‐sectional, internet‐based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert‐designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD . Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex‐ and age‐adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [ CI ] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD , and emphasize the need for appropriate healthcare resource allocation and disease recognition.
- Open Access
- 5 May 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (6) , 481-492
Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study
Background: Chronic urticaria (CU) treatment with omalizumab is considered safe in short‐term studies. Large real‐world studies focusing on the long‐term safety of omalizumab and associated factors are lacking. We aimed to investigate the spectrum of reported side effects in omalizumab‐treated CU patients in a large long‐term daily practice cohort. Methods: A multinational multicentre retrospective study was conducted at 14 specialised urticaria centres (UCAREs), including all CU patients ever treated with omalizumab until centre‐specific data lock. The prevalence of patient‐reported side effects was assessed. Results: A total of 1859 patients were included, of which 32.9% ( n = 612) reported side effects during omalizumab treatment with a wide range across centres (0%–75.5%). Fatigue (15.8%, n = 293), headache (11.6%, n = 215) and flu‐like symptoms (9.3%, n = 172) were most common. No events suggestive of anaphylaxis and no new notably prevalent side effects were reported. Hair loss was reported by 2.9% ( n = 53/1859) of patients, leading to treatment adjustment in 21.1% ( n = 8/38 with sufficient data). Patients who reported side effects were more often female (78.3% vs. 68.6%, p < 0.001), had worse disease control prior to omalizumab (Urticaria Control Test, UCT, 4.0 vs. 6.0, p < 0.001), and lower fast response (Weekly Urticaria Activity Score, UAS7, < 7 or UCT > 11 within 4 weeks, 42.6% vs. 59.5%, p < 0.001) and complete/good response rates (UAS7 < 7 or UCT > 11 at end of treatment, 72.3% vs. 84.4%, p < 0.001) compared to patients without side effects. While only 2.4% ( n = 44/1859) of patients discontinued treatment due to side effects, 5.5% ( n = 100/1859) and 12.8% ( n = 238/1859) of patients reporting side effects with insufficient (UAS7 ≥ 7 or UCT 3–11 at end of treatment) and complete/good response, respectively, remained on omalizumab. Conclusions: The safety and tolerability of omalizumab was confirmed. Notably, the wide variation in reported side effects across centres suggests that differences in awareness influence reporting. Hair loss was more prevalent than described before, warranting extra attention. Side effects were more often reported in patients whose characteristics suggest reduced effectiveness of omalizumab, possibly related to a negative association with omalizumab and suggesting increased disease burden. Availability of new therapies might increase the impact of side effects on treatment decisions, not only in omalizumab‐refractory patients but potentially even among good responders.
- 5 May 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (6) , 481-492
Open AccessSpectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long‐Term Multicentre Real‐World Study
Background: Chronic urticaria (CU) treatment with omalizumab is considered safe in short‐term studies. Large real‐world studies focusing on the long‐term safety of omalizumab and associated factors are lacking. We aimed to investigate the spectrum of reported side effects in omalizumab‐treated CU patients in a large long‐term daily practice cohort. Methods: A multinational multicentre retrospective study was conducted at 14 specialised urticaria centres (UCAREs), including all CU patients ever treated with omalizumab until centre‐specific data lock. The prevalence of patient‐reported side effects was assessed. Results: A total of 1859 patients were included, of which 32.9% ( n = 612) reported side effects during omalizumab treatment with a wide range across centres (0%–75.5%). Fatigue (15.8%, n = 293), headache (11.6%, n = 215) and flu‐like symptoms (9.3%, n = 172) were most common. No events suggestive of anaphylaxis and no new notably prevalent side effects were reported. Hair loss was reported by 2.9% ( n = 53/1859) of patients, leading to treatment adjustment in 21.1% ( n = 8/38 with sufficient data). Patients who reported side effects were more often female (78.3% vs. 68.6%, p < 0.001), had worse disease control prior to omalizumab (Urticaria Control Test, UCT, 4.0 vs. 6.0, p < 0.001), and lower fast response (Weekly Urticaria Activity Score, UAS7, < 7 or UCT > 11 within 4 weeks, 42.6% vs. 59.5%, p < 0.001) and complete/good response rates (UAS7 < 7 or UCT > 11 at end of treatment, 72.3% vs. 84.4%, p < 0.001) compared to patients without side effects. While only 2.4% ( n = 44/1859) of patients discontinued treatment due to side effects, 5.5% ( n = 100/1859) and 12.8% ( n = 238/1859) of patients reporting side effects with insufficient (UAS7 ≥ 7 or UCT 3–11 at end of treatment) and complete/good response, respectively, remained on omalizumab. Conclusions: The safety and tolerability of omalizumab was confirmed. Notably, the wide variation in reported side effects across centres suggests that differences in awareness influence reporting. Hair loss was more prevalent than described before, warranting extra attention. Side effects were more often reported in patients whose characteristics suggest reduced effectiveness of omalizumab, possibly related to a negative association with omalizumab and suggesting increased disease burden. Availability of new therapies might increase the impact of side effects on treatment decisions, not only in omalizumab‐refractory patients but potentially even among good responders.
- Open Access
- 31 December 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (12.1) , S337-S343
Impact of COVID-19 lockdowns and refugee influx on scabies presentations to dermatology outpatient clinics in Turkey
Introduction: The frequency of scabies and its relationship with the coronavirus disease 2019 (COVID-19) pandemic is a current scientific curiosity in Turkey and worldwide. The data presented in this article will help raise awareness of dermatologists in situations such as pandemic-induced quarantines where scabies can spread rapidly. Methodology: This was a retrospective study to compare patients who presented with scabies and were evaluated during the COVID-19 pandemic, with those who presented before and after the pandemic, in terms of the diagnosis ratios. In addition, the recurrence rates were compared in terms of age, nationality, and the environment in which they lived. Results: The frequency of scabies was statistically significantly higher in the post-COVID period in all quarters of the year, with a higher rate of patients in the first and last quarters, which is typical of scabies patients. However, a significant difference in recurrence rates was not detected. Conclusions: Several factors might be responsible for the increased frequency of scabies during the lockdown periods in Turkey. First, entire families, including relatives, had to live together in a crowded space. Second, there was a relative increase in doctor visits, in spite of the stay-at-home policy, owing to the overwhelming itchiness of scabies.
- 31 December 2024
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 18 (12.1) , S337-S343
Open AccessImpact of COVID-19 lockdowns and refugee influx on scabies presentations to dermatology outpatient clinics in Turkey
Introduction: The frequency of scabies and its relationship with the coronavirus disease 2019 (COVID-19) pandemic is a current scientific curiosity in Turkey and worldwide. The data presented in this article will help raise awareness of dermatologists in situations such as pandemic-induced quarantines where scabies can spread rapidly. Methodology: This was a retrospective study to compare patients who presented with scabies and were evaluated during the COVID-19 pandemic, with those who presented before and after the pandemic, in terms of the diagnosis ratios. In addition, the recurrence rates were compared in terms of age, nationality, and the environment in which they lived. Results: The frequency of scabies was statistically significantly higher in the post-COVID period in all quarters of the year, with a higher rate of patients in the first and last quarters, which is typical of scabies patients. However, a significant difference in recurrence rates was not detected. Conclusions: Several factors might be responsible for the increased frequency of scabies during the lockdown periods in Turkey. First, entire families, including relatives, had to live together in a crowded space. Second, there was a relative increase in doctor visits, in spite of the stay-at-home policy, owing to the overwhelming itchiness of scabies.